슬롯 꽁 머니

슬롯 꽁 머니 Pharma, a prominent manufacturer of fillers, has initiated the process of going public with an initial public offering (IPO). Notably, the company is drawing attention as a Korean enterprise founded by a foreign entrepreneur. Bolstering its appeal is an impressive operating profit margin, nearly reaching 20% in the previous year, firmly establishing it as a 'top-tier firm' poised to attract significant interest during the impending IPO proceedings.

On August 30th, 슬롯 꽁 머니 Pharma officially submitted its application for preliminary review for listing on the KOSDAQ market, as confirmed by the Korea Exchange (KRX) corporate disclosure channel. The preliminary review process involves a thorough evaluation by the exchange's listing review team, assessing factors such as eligibility for listing. Then, the company will submit a securities registration statement to the Financial Services Commission for public offering, subjecting it to further scrutiny regarding the suitability of its offering. If the listing review unfolds smoothly, there is a distinct possibility that 슬롯 꽁 머니 Pharma may debut on the KOSDAQ market by late 2023 or early 2024.

슬롯 꽁 머니 Pharma, formerly known as 슬롯 꽁 머니 Pharmaceuticals, was established in June 2016. It underwent a name change in March 2022 and has its headquartered in Gangnam, Seoul, with a manufacturing facility located in Chuncheon, Gangwon Province.

A distinctive facet of 슬롯 꽁 머니 Pharma is its foreign-born founder. The company's CEO, Roman Vernidub, hails from Ukraine and holds Russian citizenship. Notably, he completed his bachelor's, master's, and doctoral degrees in South Korea. Together with friends with expertise in filler injection research, Vernidub founded the company, inspired by the growth prospects of Hallyu (Korean Wave) and the Korean beauty industry.

In its inaugural year in 2016, 슬롯 꽁 머니 Pharma exported its proprietary products, including 'AVALON Fillers,' to Russia and Ukraine, achieving 0,000 (1 billion won) in sales. By 2022, the company's revenue soared to .5 million (26 billion won), accompanied by an operating profit of .6 million (4.8 billion won). These figures represent remarkable growth rates of 50% and 65%, respectively, in comparison to 2021.

슬롯 꽁 머니 Pharma boasts core technology known as 'MCO™ Tech,' designed to optimize biocompatibility through the cross-linking optimization of hyaluronic acid (HA). The company has achieved significant success across various domains, including the development of soft matter formulations and novel materials in the cosmetics industry, as well as the creation of biocompatible materials for tissue regeneration and other medical devices related to aesthetics and mesotherapy.

Explaining the significance of 'MCO™ Tech,' the company states, "This unique cross-linking technology optimizes the conditions for cross-linking agents and hyaluronic acid, ensuring maximum safety in product production." They further elucidate, "By enhancing the efficiency of cross-linking reactions, this technology forms the cornerstone for producing high-quality filler formulations, resulting in uniform particle size, stable elasticity retention, and consistent, smooth injection characteristics."

슬롯 꽁 머니 Pharma's CEO Roman Vernidub holds approximately 62% of the company's shares as of the end of 2022. Notable pre-IPO investor Xinova Investment Management owns around 24% after investing around .5 million (6 billion won) in the second half of last year. Director Park Hyun, a key executive, holds about 13% of the shares. The company plans to list with 11,352,000 shares, including 3,400,000 for public offering, and the listing will be managed by Eugene Investment & Securities and Daishin Securities.